|
|
S A Buechner, M Wernli, T Harr, S Hahn, P Itin, P Erb
J Clin Invest. 1997;
100(11):2691
doi:10.1172/JCI119814
Abstract |
Full text
| PDF

B
asal cell carcinoma (BCC) is the most common skin cancer in humans, and although metastasis rarely occurs, the tumor cells are nevertheless able to invade and destroy the surrounding tissue. Intralesional injection of IFN-alpha has been found to be highly effective in inducing BCC regression by an unknown mechanism. We show that in untreated patients, BCC cells express CD95 ligand, but not the receptor, which may allow tumor expansion by averting the attack of activated CD95 receptor-positive lymphoid effector cells. The CD95 ligand of BCC cells is functional as CD95-positive cells incubated on BCC cryosections become apoptotic and are lysed. In IFN-alpha-treated patients BCC cells express not only CD95 ligand but also CD95 receptor, whereas the peritumoral infiltrate that mainly consists of CD4+ T cells predominantly contains CD95 receptor and only few CD95 ligand-positive cells. Thus, in treated patients BCC most likely regresses by committing suicide through apoptosis induction via CD95 receptor-CD95 ligand interaction.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(45)
| Title and authors |
Publication |
Year |
Nonsurgical Treatment of Nonmelanoma Skin Cancer
Edward M. Galiczynski, Allison T. Vidimos
|
Dermatologic Clinics
|
2011 |
Aberrant expression of Fas and FasL pro-apoptotic proteins in basal cell and squamous cell carcinomas
X.-Y. Wang, R. Zhang, S. Lian
|
Clin Exp Dermatol
|
2011 |
Cell death in the skin
Saskia Lippens, Esther Hoste, Peter Vandenabeele, Patrizia Agostinis, Wim Declercq
|
Apoptosis
|
2009 |
The Molecular Basis of Cancer
Ernest C. Borden, Robert H. Silverman, Ganes Sen
|
The Molecular Basis of Cancer
|
2008 |
Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis
E Kump, J Ji, M Wernli, P Häusermann, P Erb
|
Oncogene
|
2008 |
Angiolymphoid hyperplasia with eosinophilia responding to interferon-?2B
O Oguz, M Antonov, C Demirkesen
|
Journal of the European Academy of Dermatology and Venereology
|
2007 |
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden, Ganes C. Sen, Gilles Uze, Robert H. Silverman, Richard M. Ransohoff, Graham R. Foster, George R. Stark
|
Nat Rev Drug Discov
|
2007 |
Death Receptors and Apoptosis
Emmanuel Contassot, Olivier Gaide, Lars E. French
|
Dermatologic Clinics
|
2007 |
Interferon-β-induced activation of c-Jun NH2-terminal kinase mediates apoptosis through up-regulation of CD95 in CH31 B lymphoma cells
Eiko Takada, Kuniaki Shimo, Kikumi Hata, Maira Abiake, Yasuo Mukai, Masami Moriyama, Lynn Heasley, Junichiro Mizuguchi
|
Experimental Cell Research
|
2005 |
Alpha-interferon and its effects on signal transduction pathways
Michele Caraglia, Monica Marra, Girolamo Pelaia, Rosario Maselli, Mario Caputi, Serafino A. Marsico, Alberto Abbruzzese
|
J. Cell. Physiol.
|
2005 |
|